A medical worker prepares ampoules of the Nuvaxovid vaccine against Covid-19 by Novavax at the Tegel vaccination center on February 28, 2022 in Berlin, Germany. This story was originally published on BioPharma Dive. To receive daily news and insights ...

The Food and Drug Administration (FDA) signed off Wednesday on an emergency use authorization for the Novavax COVID-19 vaccine for individuals 18 years of age and older. The Novavax vaccine is protein-based. It's made with a more conventional technology ...

There may soon be another COVID-19 vaccine on the market in the U.S. Novavax announced Monday that it has submitted a request to the Food and Drug Administration for emergency use authorization for its vaccine in adults. Unlike the mRNA vaccines from ...

The Biden administration announced Monday that it would purchase 3.2 million doses of the Novavax COVID-19 vaccine. It will be offered at no cost to states and federal partners. “We remain committed to working to ensure that anyone eligible who wants a ...

If you have ever wondered whether Novavax is undervalued, overhyped, or a hidden gem in the biotech space, you are definitely not alone. The stock recently ticked up 1.8% over the past week, but has struggled in the bigger picture,

NEW YORK -- The American biotechnology company Novavax announced on Monday that its coronavirus vaccine candidate was found to have an overall efficacy of 90.4% in a Phase 3 trial conducted across the United States and Mexico. Additional analyses of the ...

GAITHERSBURG, Md., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced a publication in Vaccines describing the immunogenic ...

Novavax, Inc. reported 3Q25 EPS loss & declining revenue, but beat revenue expectations & reaffirmed its FY25 guidance. Read more on NVAX stock here.